Why pay full price for Wegovy® when you could be eligible for savings? See how much you can save and sign up today.
With commercial insurance
Pay as little as
$25
per month*
Self pay
Starting at
$199
per month*
Limited time intro offer, $199 per month for the first 2 months, 0.25 mg or 0.5 mg doses, then $349 per month.*†
Text SAVE to 81627 to get your savings card‡
—OR—
Tap the button
By selecting the button, you will be redirected to the enrollment page for the savings card.
*A 28 day supply of the Wegovy® pen equals one month of treatment. Pay as little as $25 (maximum savings $100/month). For eligible patients only. Novo Nordisk® may modify or cancel this program at any time. See WegovyTerms.com for full terms.
†For eligible patients new to the Wegovy® Savings offer and fill through NovoCare® Pharmacy- Pay $199/month for 0.25 mg and 0.5 mg doses for up to two monthly fills through March 31, 2026. Thereafter price is $349/month. Full terms: NovoCarePharmacyTerms.com and WegovyTerms.com.
‡Text SAVE to 83757 to receive your Wegovy® digital savings offer and optional refill reminders. Message and data rates may apply. Message frequency varies. Text HELP for help. Text STOP to quit. See Terms and Conditions and privacy policy at WegovyText.com.
Free Trial Offer of Wegovy® for MASH with liver scarring
Patients diagnosed with MASH who are new to Wegovy® and have commercial or no insurance may be eligible to receive a free month's supply of the 0.25-mg dosage.§
28-day supply equivalent to 1 month of treatment. Novo Nordisk reserves the right to modify or cancel this program at any time. Government beneficiaries excluded.
Not sure about your insurance coverage?
Wegovy® may cost less than you think. We have some cost, coverage, and additional resources that may help. Learn more.
Help is a phone call away
Still have questions? Call the Wegovy® Navigation Line at 1-833-4-WEGOVY, Monday through Friday, 9:00 AM to 6:00 PM, ET.
Next
Resources and support
Wegovy® may cause serious side effects, including:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Prescribing Information and Medication Guide for Wegovy®.
Wegovy® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
This site is intended for US patients only.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use for the treatment of MASH in children under 18 years.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use for the treatment of MASH in children under 18 years.
Wegovy® may cause serious side effects, including:
Wegovy® may cause serious side effects, including:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
Wegovy® may cause serious side effects, including:
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Prescribing Information and Medication Guide for Wegovy®.
Wegovy® is a prescription medication.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
This site is intended for US patients only.
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver.
This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy® in adults with MASH.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use for the treatment of MASH in children under 18 years.